Clinical Trial Update: The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating continuous 28-day temozolomide in patients with recurrent malignant glioma who failed the standard 5-day regimen; results were posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioblastoma
• Glioma
• Oligodendroglioma

Drugs mentioned

• Temodar (Temozolomide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Glioma, Astrocytoma | Phase 2 | Status: COMPLETED | Results posted: 2010-05-17